上海荣泰健康科技股份有限公司关于注销回购股份的实施公告

Core Viewpoint - Shanghai Rongtai Health Technology Co., Ltd. has decided to change the purpose of its repurchased shares to cancellation and reduce its registered capital, which will not significantly impact the company's financial status or operational results [2][8]. Group 1: Share Repurchase Overview - The company approved a share repurchase plan on November 2, 2023, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 33 per share [3]. - The repurchase was executed starting November 8, 2023, and by November 30, 2023, the company had repurchased a total of 2,306,200 shares, accounting for 1.6594% of the total share capital at an average price of RMB 21.68 per share, totaling RMB 50,000,683 [4]. Group 2: Cancellation of Repurchased Shares - The company plans to cancel 2,303,200 shares, which represents 1.13% of the total share capital before cancellation, reducing the total share capital from 203,355,564 shares to 201,052,364 shares [2][6]. - The cancellation process is scheduled to be completed by February 3, 2026, and complies with relevant legal requirements [7]. Group 3: Impact on Company Structure - Following the cancellation, the company's shareholding structure will remain compliant with listing conditions, and the proportion of shares held by major shareholders will increase without crossing the 5% or 1% thresholds [7]. - The cancellation will not adversely affect the company's debt repayment ability or ongoing operational capacity, nor will it harm the interests of the company and its shareholders [8]. Group 4: Future Arrangements - After the cancellation of shares, the company will proceed with necessary changes in business registration and articles of association, ensuring timely information disclosure as per legal regulations [8].